ORKANasdaqPharmaceutical PreparationsFiscal year ends December 31
Oruka Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$74.48+2.55 (+3.55%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Oruka Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Oruka Therapeutics | Industry median |
|---|---|---|
| Market Cap | $4.93B | $166.30M |
| Enterprise Value | $4.06B | $88.19M |
| PB Ratio | 4.42 | 2.03 |
| P/TBV Ratio | 4.42 | 2.29 |
Income (trailing twelve months)
| Measure | Oruka Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$155.08M | -$21.40M |
| Net Income | -$132.89M | -$22.46M |
| EBITDA | -$155.08M | -$16.91M |
Returns
| Measure | Oruka Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -18.2% | -53.2% |
| Return on Assets (ROA) | -17.8% | -40.9% |
| Return on Invested Capital (ROIC) | -95.6% | -32.4% |
| Return on Capital Employed (ROCE) | -13.9% | -38.1% |
Balance sheet
| Measure | Oruka Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $873.56M | $61.43M |
| Net Cash (Debt) | $873.56M | $15.35M |
| Net Cash Per Share | $13.19 | $0.66 |
| Equity (Book Value) | $1.11B | $49.09M |
| Book Value Per Share | $16.83 | $1.37 |
| Tangible Book Value | $1.11B | $23.52M |
| Working Capital | $861.59M | $76.81M |
Financial position
| Measure | Oruka Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 38.51 | 3.34 |
| Quick Ratio | 38.03 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Oruka Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$100.92M | -$12.35M |
| Capital Expenditures | -$235.00K | -$1.08M |
| Free Cash Flow | -$101.15M | -$20.22M |
| FCF Per Share | -$1.53 | -$0.42 |
Efficiency
| Measure | Oruka Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.95M | -$703.34K |
| Employee Count | 68 | 74 |
Dividends and yields
| Measure | Oruka Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -2.69% | -23.3% |
| FCF Yield | -2.05% | -8.72% |
| Buyback Yield | -0.13% | -0.59% |
| Shareholder Yield | -0.13% | 0.00% |
Shares
| Measure | Oruka Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 66,209,700 | 58,127,000 |
| Shares Change (QoQ) | 21.7% | 0.54% |
| Float | 34,452,600 | 49,136,700 |
| Shares Held by Insiders | 48.0% | 11.6% |
| Shares Held by Institutions | 112.0% | 59.4% |
Scores
| Measure | Oruka Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 119.23 | -0.22 |
Calculated by StockData from Oruka Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.